ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学術雑誌論文等

Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines

https://hiroshima.repo.nii.ac.jp/records/2007906
https://hiroshima.repo.nii.ac.jp/records/2007906
e8d26d75-ce0c-456d-8a83-ecd848e7200e
名前 / ファイル ライセンス アクション
OncolRep_26_1369.pdf OncolRep_26_1369.pdf (568.3 KB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines
言語 en
作成者 Amatya, Vishwa Jeet

× Amatya, Vishwa Jeet

en Amatya, Vishwa Jeet

Search repository
Takeshima, Yukio

× Takeshima, Yukio

en Takeshima, Yukio

Search repository
Kushitani, Kei

× Kushitani, Kei

en Kushitani, Kei

Search repository
Yamada, Taketo

× Yamada, Taketo

en Yamada, Taketo

Search repository
Morimoto, Chikao

× Morimoto, Chikao

en Morimoto, Chikao

Search repository
Inai, Kouki

× Inai, Kouki

en Inai, Kouki

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
権利情報 Copyright (c) 2011 Spandidos Publications Ltd.
主題
主題Scheme Other
主題 CD26
主題
主題Scheme Other
主題 immunohistochemistry
主題
主題Scheme Other
主題 mesothelioma
主題
主題Scheme Other
主題 mesothelioma cell lines
主題
主題Scheme NDC
主題 490
内容記述
内容記述 Mesothelioma, a highly aggressive cancer with poor prognosis and refractory to currently available therapies show increasing trends of its incidence in Japan and other developing countries. Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. One of the new treatment strategies for mesothelioma, the humanized anti-CD26 monoclonal antibody therapy is under development. CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies. This study determined the preliminary selection criteria for humanized monoclonal anti-CD26 antibody therapy. Eighty-one epithelioid (49 differentiated and 32 less differentiated), 34 sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma cell lines were immunohistochemically examined using 8 different commercially available anti-CD26 antibodies for membranous and cytoplasmic expression. The cytoplasmic expression of CD26 was observed in all histological types of mesothelioma, while the membranous expression of CD26 was found in 88% of differentiated and 69% of less differentiated epithelioid mesothelioma, and none of sarcomatoid mesothelioma with anti-CD26 antibodies with rabbit polyclonal anti-DPP4 antibody and similar results were also obtained with goat polyclonal anti-DPP4/CD26 antibody. These antibodies absorbed with soluble human CD26 proteins do not show CD26 expression in mesothelioma tissue, suggesting these two antibodies localize true CD26 protein. Seven mesothelioma cell lines, including sarcomatoid types, also showed membranous expression of CD26 in cellblock preparation.CD26 vector transfection to CD26-negative MSTO-211H cells showed membranous expression of CD26 by flow cytometry, but not in tumor developed in NOD/SCID mice with inoculation of CD26 vector transfected MSTO-211H cells. We found that both rab
言語 en
出版者
出版者 Spandidos Publications Ltd.
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
関連情報
識別子タイプ DOI
関連識別子 10.3892/or.2011.1449
関連情報
識別子タイプ DOI
関連識別子 http://dx.doi.org/10.3892/or.2011.1449
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1021-335X
収録物識別子
収録物識別子タイプ NCID
収録物識別子 AA11016405
開始ページ
開始ページ 1369
書誌情報 Oncology Reports
Oncology Reports

巻 26, 号 6, p. 1369-1375, 発行日 2011-09-05
旧ID 34729
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-21 04:06:50.720104
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3